{
  "url": "https://struct.news/briefs/immunitybio-nearly-doubled-revenue-its-cash-balance-still-fell-45",
  "title": "ImmunityBio nearly doubled revenue. Its cash balance still fell 45%",
  "summary": "Accounts receivable climbed 141.7% year over year as the biotech’s three-month net loss widened to $230.4 million.",
  "published_at": "2026-08-04T11:50:37.115932+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "ImmunityBio, Inc.",
    "ticker": "IBRX",
    "cik": "1326110",
    "sector": "Healthcare",
    "industry": "Biotechnology"
  },
  "source_filing": {
    "form": "10-Q",
    "filed": "2026-08-04",
    "accession": "0001326110-26-000079",
    "url": "https://www.sec.gov/Archives/edgar/data/1326110/000132611026000079/ibrx-20260630.htm"
  },
  "comparison_filing": {
    "form": "10-Q",
    "filed": "2025-08-05",
    "url": "https://www.sec.gov/Archives/edgar/data/1326110/000132611025000114/ibrx-20250630.htm"
  },
  "reported_figures": [
    {
      "group": "The filing in three numbers",
      "label": "Revenue",
      "value": 113288000,
      "display": "$113.3M",
      "unit": "usd",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "sec_filing",
        "label": "Filed company results",
        "form": "10-Q",
        "accession": "0001326110-26-000079",
        "filing_date": "2026-08-04"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Revenue YoY",
      "value": 668.3146829433706,
      "display": "+668.3%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001326110-26-000079",
        "filing_date": "2026-08-04"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Operating margin",
      "value": -225.9965751006285,
      "display": "-226.0%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001326110-26-000079",
        "filing_date": "2026-08-04"
      }
    }
  ],
  "watch_next": [
    {
      "type": "liquidity_financing",
      "statement": "Management says continuing operating cash outflows create substantial doubt about going concern without additional funding or financial support.",
      "importance": "medium",
      "evidence": "As a result of continuing anticipated operating cash outflows as we commercialize our approved product in the U.S. and globally and accelerate our development efforts, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support.",
      "source_date": "2026-08-04"
    }
  ],
  "related_tickers": [
    "IBRX"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}